List of Tables
Table 1. Global Cancer Minimal Residual Disease Testing Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Cancer Minimal Residual Disease Testing Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Cancer Minimal Residual Disease Testing Market Competitive Situation by Manufacturers in 2023
Table 4. Global Cancer Minimal Residual Disease Testing Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Cancer Minimal Residual Disease Testing Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Cancer Minimal Residual Disease Testing Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Cancer Minimal Residual Disease Testing Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Cancer Minimal Residual Disease Testing Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Cancer Minimal Residual Disease Testing, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Cancer Minimal Residual Disease Testing, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Cancer Minimal Residual Disease Testing, Product Type & Application
Table 12. Global Key Manufacturers of Cancer Minimal Residual Disease Testing, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Cancer Minimal Residual Disease Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Minimal Residual Disease Testing as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Cancer Minimal Residual Disease Testing Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Cancer Minimal Residual Disease Testing Sales by Region (2019-2024) & (K Units)
Table 18. Global Cancer Minimal Residual Disease Testing Sales Market Share by Region (2019-2024)
Table 19. Global Cancer Minimal Residual Disease Testing Sales by Region (2025-2030) & (K Units)
Table 20. Global Cancer Minimal Residual Disease Testing Sales Market Share by Region (2025-2030)
Table 21. Global Cancer Minimal Residual Disease Testing Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Cancer Minimal Residual Disease Testing Revenue Market Share by Region (2019-2024)
Table 23. Global Cancer Minimal Residual Disease Testing Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Cancer Minimal Residual Disease Testing Revenue Market Share by Region (2025-2030)
Table 25. North America Cancer Minimal Residual Disease Testing Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)
Table 27. North America Cancer Minimal Residual Disease Testing Sales by Country (2025-2030) & (K Units)
Table 28. North America Cancer Minimal Residual Disease Testing Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Cancer Minimal Residual Disease Testing Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Cancer Minimal Residual Disease Testing Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)
Table 32. Europe Cancer Minimal Residual Disease Testing Sales by Country (2025-2030) & (K Units)
Table 33. Europe Cancer Minimal Residual Disease Testing Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Cancer Minimal Residual Disease Testing Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Cancer Minimal Residual Disease Testing Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Cancer Minimal Residual Disease Testing Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Cancer Minimal Residual Disease Testing Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Cancer Minimal Residual Disease Testing Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Cancer Minimal Residual Disease Testing Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Cancer Minimal Residual Disease Testing Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Cancer Minimal Residual Disease Testing Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Cancer Minimal Residual Disease Testing Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Cancer Minimal Residual Disease Testing Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Cancer Minimal Residual Disease Testing Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Cancer Minimal Residual Disease Testing Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Cancer Minimal Residual Disease Testing Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Cancer Minimal Residual Disease Testing Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Cancer Minimal Residual Disease Testing Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Type (2019-2024)
Table 51. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Type (2025-2030)
Table 52. Global Cancer Minimal Residual Disease Testing Sales Market Share by Type (2019-2024)
Table 53. Global Cancer Minimal Residual Disease Testing Sales Market Share by Type (2025-2030)
Table 54. Global Cancer Minimal Residual Disease Testing Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Cancer Minimal Residual Disease Testing Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Cancer Minimal Residual Disease Testing Revenue Market Share by Type (2019-2024)
Table 57. Global Cancer Minimal Residual Disease Testing Revenue Market Share by Type (2025-2030)
Table 58. Global Cancer Minimal Residual Disease Testing Price (US$/Unit) by Type (2019-2024)
Table 59. Global Cancer Minimal Residual Disease Testing Price (US$/Unit) by Type (2025-2030)
Table 60. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Application (2019-2024)
Table 61. Global Cancer Minimal Residual Disease Testing Sales (K Units) by Application (2025-2030)
Table 62. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application (2019-2024)
Table 63. Global Cancer Minimal Residual Disease Testing Sales Market Share by Application (2025-2030)
Table 64. Global Cancer Minimal Residual Disease Testing Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Cancer Minimal Residual Disease Testing Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Cancer Minimal Residual Disease Testing Revenue Market Share by Application (2019-2024)
Table 67. Global Cancer Minimal Residual Disease Testing Revenue Market Share by Application (2025-2030)
Table 68. Global Cancer Minimal Residual Disease Testing Price (US$/Unit) by Application (2019-2024)
Table 69. Global Cancer Minimal Residual Disease Testing Price (US$/Unit) by Application (2025-2030)
Table 70. Adaptive Biotechnologies Corporation Corporation Information
Table 71. Adaptive Biotechnologies Corporation Description and Business Overview
Table 72. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product
Table 74. Adaptive Biotechnologies Corporation Recent Developments/Updates
Table 75. ArcherDX, Inc. (Invitae Corporation) Corporation Information
Table 76. ArcherDX, Inc. (Invitae Corporation) Description and Business Overview
Table 77. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product
Table 79. ArcherDX, Inc. (Invitae Corporation) Recent Developments/Updates
Table 80. Asuragen Corporation Information
Table 81. Asuragen Description and Business Overview
Table 82. Asuragen Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Asuragen Cancer Minimal Residual Disease Testing Product
Table 84. Asuragen Recent Developments/Updates
Table 85. Arup Laboratories Corporation Information
Table 86. Arup Laboratories Description and Business Overview
Table 87. Arup Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Arup Laboratories Cancer Minimal Residual Disease Testing Product
Table 89. Arup Laboratories Recent Developments/Updates
Table 90. Bio-Rad Laboratories Corporation Information
Table 91. Bio-Rad Laboratories Description and Business Overview
Table 92. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product
Table 94. Bio-Rad Laboratories Recent Developments/Updates
Table 95. Cergentis B.V. Corporation Information
Table 96. Cergentis B.V. Description and Business Overview
Table 97. Cergentis B.V. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Cergentis B.V. Cancer Minimal Residual Disease Testing Product
Table 99. Cergentis B.V. Recent Developments/Updates
Table 100. F. Hoffmann- La Roche Ltd Corporation Information
Table 101. F. Hoffmann- La Roche Ltd Description and Business Overview
Table 102. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product
Table 104. F. Hoffmann- La Roche Ltd Recent Developments/Updates
Table 105. Guardant Health Corporation Information
Table 106. Guardant Health Description and Business Overview
Table 107. Guardant Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Guardant Health Cancer Minimal Residual Disease Testing Product
Table 109. Guardant Health Recent Developments/Updates
Table 110. ICON plc Corporation Information
Table 111. ICON plc Description and Business Overview
Table 112. ICON plc Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. ICON plc Cancer Minimal Residual Disease Testing Product
Table 114. ICON plc Recent Developments/Updates
Table 115. Invivoscribe Corporation Information
Table 116. Invivoscribe Description and Business Overview
Table 117. Invivoscribe Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Invivoscribe Cancer Minimal Residual Disease Testing Product
Table 119. Invivoscribe Recent Developments/Updates
Table 120. Laboratory Corporation of America Holdings Corporation Information
Table 121. Laboratory Corporation of America Holdings Description and Business Overview
Table 122. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product
Table 124. Laboratory Corporation of America Holdings Recent Developments/Updates
Table 125. Mission Bio Corporation Information
Table 126. Mission Bio Description and Business Overview
Table 127. Mission Bio Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Mission Bio Cancer Minimal Residual Disease Testing Product
Table 129. Mission Bio Recent Developments/Updates
Table 130. Natera, Inc. Corporation Information
Table 131. Natera, Inc. Description and Business Overview
Table 132. Natera, Inc. Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Natera, Inc. Cancer Minimal Residual Disease Testing Product
Table 134. Natera, Inc. Recent Developments/Updates
Table 135. NeoGenomics Laboratories Corporation Information
Table 136. NeoGenomics Laboratories Description and Business Overview
Table 137. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product
Table 139. NeoGenomics Laboratories Recent Developments/Updates
Table 140. Opko Health Corporation Information
Table 141. Opko Health Description and Business Overview
Table 142. Opko Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Opko Health Cancer Minimal Residual Disease Testing Product
Table 144. Opko Health Recent Developments/Updates
Table 145. Quest Diagnostics Incorporated Corporation Information
Table 146. Quest Diagnostics Incorporated Description and Business Overview
Table 147. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product
Table 149. Quest Diagnostics Incorporated Recent Developments/Updates
Table 150. Sysmex Corporation Corporation Information
Table 151. Sysmex Corporation Description and Business Overview
Table 152. Sysmex Corporation Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Sysmex Corporation Cancer Minimal Residual Disease Testing Product
Table 154. Sysmex Corporation Recent Developments/Updates
Table 155. Genetron Health Corporation Information
Table 156. Genetron Health Description and Business Overview
Table 157. Genetron Health Cancer Minimal Residual Disease Testing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 158. Genetron Health Cancer Minimal Residual Disease Testing Product
Table 159. Genetron Health Recent Developments/Updates
Table 160. Key Raw Materials Lists
Table 161. Raw Materials Key Suppliers Lists
Table 162. Cancer Minimal Residual Disease Testing Distributors List
Table 163. Cancer Minimal Residual Disease Testing Customers List
Table 164. Cancer Minimal Residual Disease Testing Market Trends
Table 165. Cancer Minimal Residual Disease Testing Market Drivers
Table 166. Cancer Minimal Residual Disease Testing Market Challenges
Table 167. Cancer Minimal Residual Disease Testing Market Restraints
Table 168. Research Programs/Design for This Report
Table 169. Key Data Information from Secondary Sources
Table 170. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Cancer Minimal Residual Disease Testing
Figure 2. Global Cancer Minimal Residual Disease Testing Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Cancer Minimal Residual Disease Testing Market Share by Type in 2023 & 2030
Figure 4. Flow Cytometry Product Picture
Figure 5. Polymerase Chain Reaction (PCR) Product Picture
Figure 6. Next-Generation Sequencing (NGS) Product Picture
Figure 7. Other Product Picture
Figure 8. Global Cancer Minimal Residual Disease Testing Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Cancer Minimal Residual Disease Testing Market Share by Application in 2023 & 2030
Figure 10. Hematological Malignancies
Figure 11. Leukemia
Figure 12. Lymphoma
Figure 13. Solid Tumors
Figure 14. Other
Figure 15. Global Cancer Minimal Residual Disease Testing Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Cancer Minimal Residual Disease Testing Market Size (2019-2030) & (US$ Million)
Figure 17. Global Cancer Minimal Residual Disease Testing Sales (2019-2030) & (K Units)
Figure 18. Global Cancer Minimal Residual Disease Testing Average Price (US$/Unit) & (2019-2030)
Figure 19. Cancer Minimal Residual Disease Testing Report Years Considered
Figure 20. Cancer Minimal Residual Disease Testing Sales Share by Manufacturers in 2023
Figure 21. Global Cancer Minimal Residual Disease Testing Revenue Share by Manufacturers in 2023
Figure 22. The Global 5 and 10 Largest Cancer Minimal Residual Disease Testing Players: Market Share by Revenue in 2023
Figure 23. Cancer Minimal Residual Disease Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 24. Global Cancer Minimal Residual Disease Testing Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 25. North America Cancer Minimal Residual Disease Testing Sales Market Share by Country (2019-2030)
Figure 26. North America Cancer Minimal Residual Disease Testing Revenue Market Share by Country (2019-2030)
Figure 27. United States Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe Cancer Minimal Residual Disease Testing Sales Market Share by Country (2019-2030)
Figure 30. Europe Cancer Minimal Residual Disease Testing Revenue Market Share by Country (2019-2030)
Figure 31. Germany Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Russia Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific Cancer Minimal Residual Disease Testing Sales Market Share by Region (2019-2030)
Figure 37. Asia Pacific Cancer Minimal Residual Disease Testing Revenue Market Share by Region (2019-2030)
Figure 38. China Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Japan Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. South Korea Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. India Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Australia Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. China Taiwan Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Southeast Asia Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Cancer Minimal Residual Disease Testing Sales Market Share by Country (2019-2030)
Figure 46. Latin America Cancer Minimal Residual Disease Testing Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Cancer Minimal Residual Disease Testing Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Cancer Minimal Residual Disease Testing Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Cancer Minimal Residual Disease Testing Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Cancer Minimal Residual Disease Testing by Type (2019-2030)
Figure 56. Global Revenue Market Share of Cancer Minimal Residual Disease Testing by Type (2019-2030)
Figure 57. Global Cancer Minimal Residual Disease Testing Price (US$/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Cancer Minimal Residual Disease Testing by Application (2019-2030)
Figure 59. Global Revenue Market Share of Cancer Minimal Residual Disease Testing by Application (2019-2030)
Figure 60. Global Cancer Minimal Residual Disease Testing Price (US$/Unit) by Application (2019-2030)
Figure 61. Cancer Minimal Residual Disease Testing Value Chain
Figure 62. Cancer Minimal Residual Disease Testing Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
